What Precision Biosensor does

Precision Biosensor Inc. is a South Korea-based in vitro diagnostics (IVD) company that develops, manufactures, and commercializes point-of-care testing (POCT) platforms for both animal and human healthcare. Founded in 2015 through the merger of Nano-Ditech Corp. (US-based cartridge manufacturer) and Terawave Inc. (Korea-based analyzer developer with satellite camera technology), the company is publicly listed on KOSDAQ (ticker 335810) with GDH Pharmaceuticals (Kwangdong Pharmaceutical) as its majority shareholder (~54.73%). The company serves two primary verticals: veterinary/animal health (with the Exdia PT10V clinical chemistry platform covering companion animals, large animals, bovine, and equine) and human healthcare/IVD (with the Exdia TRF Plus immunodiagnostics platform and PT10 clinical chemistry cartridges covering cardiovascular, liver, infectious disease, lipid, inflammatory, body composition, and HbA1c categories).

The company's core technology is built on two proprietary platforms: (1) Time-Resolved Fluorescence (TRF) immunodiagnosis, which uses image-based ultrasensitive fluorescence detection with Europium chelates and GHz-level optical timing control to detect single-digit picograms of biomarkers, and (2) a Multiplex Clinical Chemistry platform with lab-on-a-chip microfluidics enabling simultaneous analysis of up to 17 analytes from a 2-inch cartridge using only 70 microliters of sample. Precision Biosensor claims to be the only company globally providing image-based TRF POCT products at this sensitivity level and reasonable price point. The company holds over 370 diagnostic-related patents and maintains ISO 13485, ISO 27001, FDA, CE/IVDR, MFDS, PMDA, and KGMP certifications, with manufacturing facilities in Daejeon (5,521m² HQ with capacity for 5M+ immuno and 2M+ clinical chemistry cartridges annually) and a second Daejeon factory under construction, plus a US subsidiary (Nano-Ditech Corp.) in Cranbury, New Jersey.

The company operates a multi-channel distribution model anchored by long-term exclusive supply contracts with three major global IVD distributors: Antech Diagnostics (15-year, ~118.2 billion KRW contract for animal clinical chemistry), NIPRO Corporation (Japan distribution for Atlyze V/Atpanel V launched June 2026), and Sekisui Diagnostics (10-year contracts for RSV, COVID-19, and Combo rapid antigen tests in North America). Revenue is generated primarily through cartridge sales (consumables) and analyzer hardware sales to veterinary clinics, hospitals, and distributors. In 2023, consolidated revenue reached 204 billion KRW (~$150M USD), with a 51% CAGR from 2018 to 2021 that earned FT-Statista Asia-Pacific High Growth Companies listing. The company completed an absorption merger with Citibio in February 2026, integrating the LampFly Dx S ultra-compact blood glucose diagnostic product and strengthening R&D capabilities under the GDH Pharmaceuticals group.

Name

Precision Biosensor

Legal name

Precision Biosensor, Inc.

Website

https://precision-bio.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Precision Biosensor is a South Korean IVD company that develops and manufactures point-of-care diagnostic platforms (TRF immunodiagnostics and multiplex clinical chemistry) for veterinary and human healthcare, distributing globally through exclusive long-term contracts with Antech, NIPRO, and Sekisui Diagnostics.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics / Point-of-Care Testing

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Chemistry & Immunoassay Systems (HLAHAAAA)

akta.pro secondary industries

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Point-of-Care & In-Clinic Diagnostics (Rapid Tests, Benchtop Analyzers) (HLAMADAI)

Keywords

• Point-of-care diagnostics
• In vitro diagnostics
• Immunodiagnostic analyzers
• Veterinary clinical chemistry
• Time-resolved fluorescence assays

Headquarters

HQ city

Daejeon

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Infrastructure, Operations, Marketing or Sales, Personnel

Revenue model

1. Clinical Chemistry Cartridge Sales: Sale of clinical chemistry diagnostic cartridges for both animal (Exdia PT10V) and human use. Cartridges are sold in packs for specific test panels (e.g., Liver 11V, Kidney 8V, Comprehensive Plus 17V). This is the primary growth driver post-COVID, expanding globally.
2. Diagnostic Analyzer Hardware Sales: Sale of Exdia PT10V and Exdia TRF Plus analyzers/instruments to veterinary clinics, hospitals, and distribution partners. Compact A4-size clinical chemistry platforms sold alongside cartridges.
3. Immunodiagnostic Products: Sale of immunodiagnostic products including cardiovascular, infectious disease, and other biomarker-based test cartridges. Revenue declined post-COVID but remains part of the portfolio.
4. Subsidiary (Nano-Ditech) Product Sales: Nano-Ditech Corp, the US subsidiary in New Jersey, generates revenue from respiratory rapid antigen tests (RSV, COVID-19, Combo) supplied to Sekisui Diagnostics under long-term supply contracts.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Precision Biosensor manufactures and sells point-of-care in vitro diagnostic (IVD) analyzers and proprietary single-use cartridges built on two technology platforms: Time-Resolved Fluorescence (TRF) immunodiagnosis for high-sensitivity biomarker detection and Multiplex Clinical Chemistry. The portfolio serves both animal diagnostics (Exdia PT10V for veterinary clinics and animal hospitals; Atlyze V for Japan) and human diagnostics (Exdia TRF Plus immunodiagnostics, Exdia PT10 clinical chemistry, HA100 platform, and respiratory rapid antigen tests via Nano-Ditech), with products distributed globally through enterprise supply contracts and regional distribution partners.

Product overview

Precision Biosensor offers a portfolio of in vitro diagnostic (IVD) products centered on two main technology platforms: TRF (Time-Resolved Fluorescence) immunodiagnostics and multiplex clinical chemistry. The core Exdia PT10V is a point-of-care clinical chemistry platform for animal diagnostics (companion animals, large animals, bovine, equine) with over 11 cartridge types enabling simultaneous analysis of up to 17 parameters. The human-focused portfolio includes Exdia TRF Plus for immunodiagnostics and Exdia PT10 for clinical chemistry, with cartridges covering cardiovascular, liver, infectious disease, lipid, inflammatory, body composition, tumor/hormone/vitamin, and HbA1c categories. The company also offers digital health solutions including PT10 Report System (PRS) for data management, and has expanded through partnerships with Antech Diagnostics, NIPRO Corporation, and SEKISUI Diagnostics for global distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• Exdia PT10V Point-of-care clinical chemistry analyzer for companion animals. A4-sized, 2kg portable device with 4.3" touchscreen that analyzes up to 17 parameters in 10 minutes using only 70μL of blood sample. Supports multiple cartridge types for presurgical, liver, kidney, electrolyte, and comprehensive testing. Sold to veterinary clinics, hospitals, and animal reference laboratories globally.
• Atlyze V Animal clinical chemistry diagnostic device launched in Japan through NIPRO Corporation partnership. Measures up to 17 items from 70μL plasma or serum samples with compact design and simple operation, enabling immediate on-site results versus external reference laboratory testing.
• Atpanel V Dedicated reagent for Atlyze V animal clinical chemistry diagnostic equipment, developed and supplied in partnership with NIPRO Corporation for the Japanese market.
• Exdia TRF Plus Analyzer Time-Resolved Fluorescence immunodiagnostics platform for human diagnostics. Uses image-based TRF technology capable of detecting single-digit picograms of biomarkers. Enables high-sensitivity point-of-care testing for cardiovascular, infectious disease, and other biomarker-based tests in hospital and clinical settings.
• HA100 Immunodiagnostics Platform Immunodiagnostics platform that received new regulatory approval and was featured at the MEDICA 2025 exhibition. Used for high-sensitivity biomarker-based point-of-care testing in clinical and hospital settings.
• Nano-Check COVID-19 Antigen Test Rapid COVID-19 antigen test developed by Nano-Ditech Corporation (US subsidiary). Supplied under a 10-year exclusive contract with Sekisui Diagnostics for North American distribution.
• Combo Rapid Diagnostic (COVID-19/Influenza) Multiplex rapid diagnostic product for simultaneous detection of COVID-19 and Influenza A&B. Planned market launch August 2026 through the Sekisui Diagnostics partnership in North America.
• LampFly Dx S Ultra-compact blood glucose diagnostic product developed by Citibio, integrated into Precision Biosensor's portfolio following the 2025 merger. Designed for home self-testing use.
• Exdia PT10V Clinical Chemistry Cartridges Multi-cartridge menu for the Exdia PT10V animal analyzer covering presurgical screening, liver, kidney, electrolyte, large animal, comprehensive plus, bovine, equine, liver monitoring, kidney monitoring, and diabetes panels. Sold in packs for each test panel.
• PT10V Cartridges (Human) Human clinical chemistry cartridges for the Exdia PT10 clinical chemistry platform, covering cardiovascular, liver, infectious disease, lipid, inflammatory, body composition, tumor/hormone/vitamin, and HbA1c diagnostic categories.

Named customers4 records

Segments3 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Sekisui DiagnosticscoreStrategic or Co-development Partner · 1 May 2026Partnership scope expanded to include Combo (COVID-19/Influenza) rapid diagnostic products for the North American market. Target market launch August 2026. Partnership also encompasses future respiratory diagnostic product development and commercialization, representing a strategic deepening beyond pure supply.
• Sekisui DiagnosticscoreChannel Partner/ Reseller/ Distributor · 1 November 2025Long-term exclusive supply contracts (10 years each) for respiratory rapid antigen diagnostic products: RSV test (March 2025), COVID-19 test (November 2025), and Combo (COVID-19/Influenza) test (May 2026). Sekisui distributes Nano-Ditech's products through its extensive North American distribution network. Strategic partnership includes future new product development and commercialization cooperation.
• CitibiocoreStrategic or Co-development Partner · 1 November 2025Precision Biosensor merged with Citibio (absorbed merger) in 2025-2026. Citibio, a diagnostic and healthcare specialist established in 2018 with Gwangdong Pharmaceutical as its largest shareholder, has proprietary ultra-compact blood glucose diagnostic products (LampFly Dx S) and strong R&D capabilities in immunodiagnostics. The merger integrates R&D through manufacturing to sales/distribution, strengthening the overall value chain.
• Antech Diagnostics Germany GmbHcoreChannel Partner/ Reseller/ Distributor · 1 November 2025Integrated contract extension covering Europe and most regions outside North America and Japan. Antech Diagnostics Germany (formerly Scil Animal Care) operates 90+ reference labs globally and provides point-of-care diagnostics, imaging solutions, cloud-based data services, and veterinary practice management systems. The 10+ year partnership was restructured and expanded following the Heska-Scil merger integration.
• MEDICA 2025 / Various Global PartnersminorGTM or Marketing Partner · 1 November 2025Participated in MEDICA 2025 (world's largest medical device exhibition with 70+ countries, 5,000+ companies, 80,000+ attendees) to showcase products and meet with global partners. Conducted meetings with existing partners to share business progress and 2026 plans, and with potential partners to discuss cooperation models and long-term business development.
• NIPRO CorporationcoreChannel Partner/ Reseller/ Distributor · 1 December 2024Japanese market partnership for animal clinical chemistry diagnostic equipment 'Atlyze V' and reagent 'Atpanel V'. NIPRO is a major Japanese medical company (Tokyo Stock Exchange listed, ~43.3 billion USD FY2025 revenue, 40,000+ employees). Regulatory filings completed with Japan's Ministry of Agriculture, Forestry and Fisheries in March 2026. Products launched June 2026. Joint development of new reagents also planned.
• Antech Diagnostics (including Antech Diagnostics Germany GmbH)coreChannel Partner/ Reseller/ Distributor · 1 July 2022Long-term exclusive supply contract (15 years, approximately 1,182 billion KRW) for animal clinical chemistry diagnostic analyzers (Exdia PT10V) and 11 types of cartridges. Antech distributes to its global network of 60+ animal diagnostic reference laboratories. Partnership restructured in 2025 to cover Europe and most regions outside North America and Japan, with expanded contract scope.
• RIGHT Fund (Research Investment for Global Health Technology Fund)minorStrategic or Co-development Partner · 1 January 2019Collaboration with RIGHT Fund on R&D of Exdia Mobile product — a more compact and higher-connectivity diagnostic device compared to existing products, as well as a combination product for simultaneous detection of Influenza A&B and COVID-19 infection.

Scale indicators11 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Sysmex: Global hematology/IVD incumbent expanding into clinical chemistry and POCT adjacencies. Broad incumbent in the same IVD/POCT space, particularly relevant as a Japanese competitor also accessed through NIPRO-type distribution channels.
• Zoetis: Animal health giant with a growing diagnostics segment including POCT. Operates as a broad incumbent whose diagnostics portfolio overlaps Precision Biosensor's veterinary chemistry cartridges but spans a much wider therapeutic and species footprint.
• Abbott Point of Care (i-STAT): Operator of the i-STAT system, the dominant handheld clinical chemistry/immunoassay POCT platform in hospitals worldwide. Broad incumbent in the same POCT clinical chemistry category Precision Biosensor targets with Exdia PT10 and Exdia TRF Plus.

Emerging players

• EKF Diagnostics: Smaller IVD/POCT company focused on point-of-care clinical chemistry (QuikRead, Hemo Control) and specialty diagnostics. Emerging player with overlapping POCT chemistry scope and cartridge-style reagent economics, though smaller scale and narrower menu than Precision Biosensor.

Direct peers

• Boditech Med: Korean IVD/POCT peer with an ichroma immunodiagnostic POCT platform and cartridge-based recurring revenue model. Closest Korean-domestic direct peer across POCT immunodiagnostics and clinical chemistry cartridges.
• Heska (Mars Petcare): Veterinary point-of-care diagnostics and reference lab services provider; now part of Mars Petcare/Antech network. Directly comparable to Precision Biosensor's Exdia PT10V platform and the channel relationship with Antech Diagnostics Germany (formerly Scil Animal Care, originally Heska's European arm).
• SD Biosensor: Korean POCT/IVD company with overlapping rapid antigen test, immunodiagnostic, and clinical chemistry products on a global channel. Closest geographic and product peer to Precision Biosensor's Nano-Ditech respiratory franchise and Exdia TRF platform.
• Nova Biomedical: Specialist in hospital-side POCT clinical chemistry and critical care blood gas analyzers (Stat Profile, Prime Plus). Directly comparable product/customer set to Precision Biosensor's clinical chemistry cartridge business and overlapping technology platform scope.
• QuidelOrtho: Specialized POCT and immunoassay diagnostics provider (Triage, Sofia rapid antigen, Vitros systems). Direct peer in POCT immunodiagnostics and rapid antigen respiratory testing, with similar reliance on cartridge-based recurring revenue and hospital/physician office channels.
• IDEXX Laboratories: Global leader in companion animal diagnostics, including point-of-care analyzers and consumables. Most directly comparable to Precision Biosensor's veterinary Exdia PT10V business in target customer (vet clinics), product category (POCT chemistry/immunoassay), and razor/blade economics on cartridges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@precisionbiosensor
• LinkedInlinkedin.com/company/72986144

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision Biosensor